It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%, in 2 years. This means that 11,784 people would be spared blindness in that time period.
Bressler, Neil M., Quan V. Doan, Rohit Varma, Paul P. Lee, Ivan J. suner, Chantal Dolan, Mark D. Danese, Elaine Yu, Irwin Tran and Soshana Colman. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/427350